AION Labs, an Israel-based AI-enabled drug discovery partnership, has launched a new startup company called CombinAble.AI to accelerate therapeutics development by focusing on antibody design challenges. CombinAble.AI was established after an AION Labs startup challenge aimed at using AI for therapeutic antibodies. The company will use a platform integrating AI and computational methods for biomolecule simulations to create new biotherapeutics. This approach involves utilizing data from AION Labs’ pharma partners and publicly available data. CombinAble.AI’s CEO, Dr. Daria Kokh, highlighted the importance of AION Labs’ support in shaping the company. CombinAble.AI joins other AION portfolio companies in advancing research and therapeutic development.
Source link
AION Labs launches CombinAble.AI to design antibodies for therapeutic development
